The effect of 15(R)-15-methyl prostaglandin E2 on meal-stimulated gastric acid secretion, serum gastrin, and pancreatic polypeptide in duodenal ulcer patients.
The effects of 100-microgram of 15(R)-15-methyl prostaglandin E2 on meal-stimulated acid secretion, serum gastrin, and pancreatic polypeptide concentrations were measured in patients with duodenal ulcer. The drug given in encapsulated or unencapsulated form significantly reduced gastric acid secretion by 59% or 70%, respectively. Rises in serum gastrin and pancreatic polypeptide concentrations after the meal were significantly blunted by 15(R)-15-methyl prostaglandin E2. This dose of prostaglandin led to no side effects and merits clinical evaluation in the treatment of peptic ulcer disease.
D000328:Adult; D002214:Capsules; D004381:Duodenal Ulcer / Q000378:metabolism*; D004435:Eating; D005750:Gastric Juice / Q000378:metabolism*; D005755:Gastrins / Q000097:blood*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010179:Pancreas / Q000187:drug effects* / Q000378:metabolism; D010191:Pancreatic Polypeptide / Q000378:metabolism*; D011459:Prostaglandins E, Synthetic / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*
D002214:Capsules; D005755:Gastrins; D011459:Prostaglandins E, Synthetic; D010191:Pancreatic Polypeptide